BACKGROUND Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of conditions,
progressing from mild steatosis to advanced fibrosis. Sarcopenia, characterized by …

Introduction: Sarcopenia is increasingly recognized in patients with nonalcoholic liver
disease (NAFLD). Initially recognized as a consequence of advanced liver disease, there is …

Introduction Nonalcoholic fatty liver disease (NAFLD) is currently one of the most common
liver diseases worldwide. Recent data suggest that loss of skeletal muscle mass and …

Background Sarcopenia recognises insulin resistance and obesity as risk factors, and is
frequently associated with cardiometabolic disorders, including non‐alcoholic fatty liver …

Sarcopenia, described as the loss of muscle mass and/or strength, is gaining importance as
it can be increasingly related to many chronic diseases. It is also associated with chronic …

Nonalcoholic fatty liver disease (NAFLD) is now the most common cause of chronic liver
disease. NAFLD encompasses a group of conditions where there is an accumulation of …

Sarcopenia is a common clinical symptom in aging and patients with wasting diseases,
characterized by a decreased skeletal muscle mass. As a consequence of lifestyle change …

Background & Aims Nonalcoholic fatty liver disease (NAFLD) and sarcopenia can be
associated with advanced liver disease. Our aim was to assess the association between …

The global epidemic of obesity and metabolic syndrome in an aging population have led to
an increased prevalence of many chronic conditions including nonalcoholic fatty liver …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver
disease. As the second stage of developing steatosis, nonalcoholic hepatitis (NASH) carries …